Zai Lab (ZLAB) Competitors $37.33 -0.68 (-1.79%) Closing price 03/20/2025 04:00 PM EasternExtended Trading$37.67 +0.34 (+0.91%) As of 03/20/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ZLAB vs. SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, PCVX, and QGENShould you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Zai Lab vs. Summit Therapeutics Intra-Cellular Therapies Genmab A/S Moderna Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S Sarepta Therapeutics Vaxcyte Qiagen Summit Therapeutics (NASDAQ:SMMT) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and institutional ownership. Does the MarketBeat Community favor SMMT or ZLAB? Summit Therapeutics received 76 more outperform votes than Zai Lab when rated by MarketBeat users. However, 64.43% of users gave Zai Lab an outperform vote while only 58.40% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes30658.40% Underperform Votes21841.60% Zai LabOutperform Votes23064.43% Underperform Votes12735.57% Do analysts recommend SMMT or ZLAB? Summit Therapeutics currently has a consensus price target of $34.11, suggesting a potential upside of 75.47%. Zai Lab has a consensus price target of $47.37, suggesting a potential upside of 26.89%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Zai Lab 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is SMMT or ZLAB more profitable? Summit Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -76.14%. Zai Lab's return on equity of -36.97% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Zai Lab -76.14%-36.97%-27.10% Which has better earnings and valuation, SMMT or ZLAB? Zai Lab has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K20,486.43-$614.93M-$0.31-62.71Zai Lab$398.99M10.26-$334.62M-$2.59-14.41 Does the media favor SMMT or ZLAB? In the previous week, Zai Lab had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for Zai Lab and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.01 beat Zai Lab's score of 0.81 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SMMT or ZLAB? Summit Therapeutics has a beta of -1.04, indicating that its share price is 204% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Do institutionals and insiders hold more shares of SMMT or ZLAB? 4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 88.3% of Summit Therapeutics shares are held by insiders. Comparatively, 13.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryZai Lab beats Summit Therapeutics on 11 of the 19 factors compared between the two stocks. Remove Ads Get Zai Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZLAB vs. The Competition Export to ExcelMetricZai LabPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.09B$7.11B$5.72B$8.09BDividend YieldN/A2.75%4.41%4.08%P/E Ratio-13.486.2624.1518.97Price / Sales10.26235.15398.8189.86Price / CashN/A65.6738.1134.64Price / Book4.646.606.934.35Net Income-$334.62M$141.70M$3.18B$246.92M7 Day Performance-2.28%1.24%1.08%1.37%1 Month Performance10.51%-6.11%1.72%-6.51%1 Year Performance116.41%-4.24%14.42%3.35% Zai Lab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZLABZai Lab2.3649 of 5 stars$37.33-1.8%$47.37+26.9%+116.9%$4.09B$398.99M-13.481,950Insider TradeSMMTSummit Therapeutics1.7661 of 5 stars$20.13-3.2%$34.11+69.5%+407.6%$14.85B$700,000.00-71.89110Positive NewsGap DownITCIIntra-Cellular Therapies3.6032 of 5 stars$131.45+0.1%$106.08-19.3%+95.8%$13.98B$680.50M-151.09560Analyst ForecastPositive NewsGMABGenmab A/S4.1771 of 5 stars$20.80+1.4%$41.33+98.7%-32.6%$13.76B$21.53B11.952,204Analyst RevisionMRNAModerna4.2069 of 5 stars$34.71+0.3%$59.60+71.7%-68.5%$13.39B$3.20B-3.743,900VTRSViatris2.1862 of 5 stars$9.25+1.6%$10.50+13.5%-20.5%$11.04B$14.74B-12.5037,000RDYDr. Reddy's Laboratories2.973 of 5 stars$13.23+4.3%$17.00+28.5%-6.7%$11.04B$311.31B21.0624,800Analyst RevisionPositive NewsASNDAscendis Pharma A/S2.9681 of 5 stars$168.84+10.4%$202.36+19.9%+13.2%$10.25B$363.64M-23.781,017Analyst ForecastPositive NewsHigh Trading VolumeSRPTSarepta Therapeutics4.6366 of 5 stars$101.35+4.3%$170.41+68.1%-41.7%$9.83B$1.90B81.081,314Analyst ForecastOptions VolumePCVXVaxcyte2.374 of 5 stars$75.23+1.2%$147.50+96.1%+7.7%$9.69BN/A-16.35160Positive NewsQGENQiagen4.0779 of 5 stars$39.85+0.9%$47.71+19.7%-7.9%$8.84B$1.98B110.955,967Short Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Moderna Alternatives Viatris Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Sarepta Therapeutics Alternatives Vaxcyte Alternatives Qiagen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZLAB) was last updated on 3/21/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
